Invivyd (IVVD) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $0.67, +10.03% vs the prior close of $0.61.
- Volume 3.29M shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IVVD jumps 10.0% to $0.67. Closed at $0.67, +10.03% vs the prior close of $0.61. Day range $0.61–$0.68, opened at $0.62.
IVVD daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — IVVD jumps 10.0% to $0.67
- Closed at $0.67, +10.03% vs the prior close of $0.61. Day range $0.61–$0.68, opened at $0.62.
- Volume was 3.29M shares, 0.6x its 50-day average of 5.48M — lighter than usual.
- Price is -18.5% vs its 50-day average ($0.82) and -47.2% vs its 200-day average ($1.27).
- 52-week range $0.53–$3.07; today's close sits at 6% of that range, 78.2% below the 52-week high.
Oct 14, 2026 — IVVD slides 5.9% to $0.61, a 1-month low, 3 down days in a row
- Closed at $0.61, -5.88% vs the prior close of $0.65. Day range $0.60–$0.64, opened at $0.64.
- Volume was 4.00M shares, 0.7x its 50-day average of 5.49M.
- Price is -25.8% vs its 50-day average ($0.82) and -52.4% vs its 200-day average ($1.28).
- 52-week range $0.53–$3.07; today's close sits at 3% of that range, 80.2% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — IVVD slides 4.0% to $0.65, a 1-month low
- Closed at $0.65, -4.01% vs the prior close of $0.67. Day range $0.64–$0.67, opened at $0.66.
- Volume was 3.66M shares, 0.7x its 50-day average of 5.47M.
- Price is -21.1% vs its 50-day average ($0.82) and -49.8% vs its 200-day average ($1.29).
- 52-week range $0.53–$3.07; today's close sits at 5% of that range, 79.0% below the 52-week high.
Oct 12, 2026 — IVVD slides 6.7% to $0.67, a 1-month low
- Closed at $0.67, -6.66% vs the prior close of $0.72. Day range $0.66–$0.72, opened at $0.71.
- Volume was 2.82M shares, 0.5x its 50-day average of 5.45M — lighter than usual.
- Price is -17.6% vs its 50-day average ($0.82) and -48.1% vs its 200-day average ($1.30).
- 52-week range $0.53–$3.07; today's close sits at 6% of that range, 78.1% below the 52-week high.
Oct 9, 2026 — IVVD jumps 3.0% to $0.72
- Closed at $0.72, +3.00% vs the prior close of $0.70. Day range $0.69–$0.74, opened at $0.70.
- Volume was 2.77M shares, 0.5x its 50-day average of 5.46M — lighter than usual.
- Price is -11.4% vs its 50-day average ($0.81) and -44.9% vs its 200-day average ($1.31).
- 52-week range $0.53–$3.07; today's close sits at 8% of that range, 76.5% below the 52-week high.
Oct 8, 2026 — IVVD slides 4.0% to $0.70, a 1-month low on 2.0x normal volume
- Closed at $0.70, -3.98% vs the prior close of $0.73. Day range $0.67–$0.74, opened at $0.74.
- Volume was 10.44M shares, 2.0x its 50-day average of 5.33M — unusually heavy trading.
- Price is -13.7% vs its 50-day average ($0.81) and -46.9% vs its 200-day average ($1.32).
- 52-week range $0.53–$3.07; today's close sits at 7% of that range, 77.2% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — IVVD slides 9.6% to $0.73, a 1-month low on 1.8x normal volume
- Closed at $0.73, -9.55% vs the prior close of $0.81. Day range $0.73–$0.82, opened at $0.80.
- Volume was 9.47M shares, 1.8x its 50-day average of 5.19M — unusually heavy trading.
- Price is -9.8% vs its 50-day average ($0.81) and -45.1% vs its 200-day average ($1.33).
- 52-week range $0.53–$3.07; today's close sits at 8% of that range, 76.3% below the 52-week high.
Oct 6, 2026 — IVVD slides 3.9% to $0.81
- Closed at $0.81, -3.93% vs the prior close of $0.84. Day range $0.80–$0.85, opened at $0.85.
- Volume was 5.05M shares, 1.0x its 50-day average of 5.17M.
- Price is +0.1% vs its 50-day average ($0.81) and -39.6% vs its 200-day average ($1.33).
- 52-week range $0.53–$3.07; today's close sits at 11% of that range, 73.7% below the 52-week high.
Oct 5, 2026 — IVVD rises 2.1% to $0.84
- Closed at $0.84, +2.07% vs the prior close of $0.82. Day range $0.79–$0.85, opened at $0.82.
- Volume was 5.42M shares, 1.1x its 50-day average of 5.13M.
- Price is +4.7% vs its 50-day average ($0.80) and -37.5% vs its 200-day average ($1.34).
- 52-week range $0.53–$3.07; today's close sits at 12% of that range, 72.7% below the 52-week high.
Oct 2, 2026 — IVVD rises 0.6% to $0.82
- Closed at $0.82, +0.61% vs the prior close of $0.82. Day range $0.77–$0.84, opened at $0.83.
- Volume was 7.13M shares, 1.4x its 50-day average of 5.06M.
- Price is +3.2% vs its 50-day average ($0.80) and -39.1% vs its 200-day average ($1.35).
- 52-week range $0.53–$3.07; today's close sits at 12% of that range, 73.2% below the 52-week high.
IVVD latest news & SEC filings
Every SEC filing by or about IVVD in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 8.01 — Reported other events the company considers important.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lee Timothy Edward sold 18,425 shares at $0.84 (≈$15.48K) on Aug 18, 2026
- Lee Timothy Edward sold 22,355 shares at $0.72 (≈$16.10K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Green Julie sold 18,425 shares at $0.84 (≈$15.48K) on Aug 18, 2026
- Green Julie sold 22,355 shares at $0.72 (≈$16.10K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Duke William E. sold 18,425 shares at $0.84 (≈$15.48K) on Aug 18, 2026
- Duke William E. sold 22,355 shares at $0.72 (≈$16.10K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $14.29M (prior year $11.79M) (+21.2% vs Jun 30, 2025)
- Net income: -$44.39M (prior year -$14.66M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.14 (prior year -$0.12) (loss widened vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Jul 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade IVVD
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 5, 2026, Jan 8, 2026. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.99% (largest 35.1%). That is a volatile stock.
- Liquidity: about 7.82M shares (≈$5.23M) trade per day on average.
- 52-week position: $0.67 vs a range of $0.53–$3.07 (6% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 1 open-market buys, 20 sales; latest: William E. Duke sold 18,425 shares on Aug 18, 2026.
- Latest filings: 8-K Sep 29, 2026; 8-K Sep 1, 2026; 10-Q Aug 13, 2026.
- Share count: 294.76M shares outstanding (Jul 30, 2026), +145.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
IVVD market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.62 | 0.68 | 0.61 | 0.67 | 3.29M |
| Oct 14, 2026 | 0.64 | 0.64 | 0.60 | 0.61 | 4.00M |
| Oct 13, 2026 | 0.66 | 0.67 | 0.64 | 0.65 | 3.66M |
| Oct 12, 2026 | 0.71 | 0.72 | 0.66 | 0.67 | 2.82M |
| Oct 9, 2026 | 0.70 | 0.74 | 0.69 | 0.72 | 2.77M |
| Oct 8, 2026 | 0.74 | 0.74 | 0.67 | 0.70 | 10.44M |
| Oct 7, 2026 | 0.80 | 0.82 | 0.73 | 0.73 | 9.47M |
| Oct 6, 2026 | 0.85 | 0.85 | 0.80 | 0.81 | 5.05M |
| Oct 5, 2026 | 0.82 | 0.85 | 0.79 | 0.84 | 5.42M |
| Oct 2, 2026 | 0.83 | 0.84 | 0.77 | 0.82 | 7.13M |
| Oct 1, 2026 | 0.87 | 0.90 | 0.81 | 0.82 | 5.46M |
| Sep 30, 2026 | 0.86 | 0.88 | 0.82 | 0.87 | 8.39M |
| Sep 29, 2026 | 0.92 | 0.93 | 0.77 | 0.85 | 31.29M |
| Sep 28, 2026 | 0.98 | 1.01 | 0.94 | 0.95 | 11.01M |
| Sep 25, 2026 | 0.92 | 0.95 | 0.90 | 0.93 | 3.49M |
| Sep 24, 2026 | 0.95 | 0.97 | 0.89 | 0.91 | 6.00M |
| Sep 23, 2026 | 0.95 | 0.96 | 0.91 | 0.92 | 6.91M |
| Sep 22, 2026 | 1.01 | 1.01 | 0.91 | 0.96 | 8.44M |
| Sep 21, 2026 | 0.83 | 1.05 | 0.82 | 1.02 | 15.01M |
| Sep 18, 2026 | 0.76 | 0.79 | 0.73 | 0.75 | 6.28M |
About Invivyd
Invivyd (IVVD) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in NEW HAVEN, CT. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1832038.
IVVD board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Paul Bolno | Director | May 21, 2026 |
| Tamsin Berry | Director | May 21, 2026 |
| Marc Elia | Chief Executive Officer | Sep 1, 2026 |
| Terrance Mcguire | Director | May 21, 2026 |
| Kevin F Mclaughlin | Director | May 21, 2026 |
| Ajay Royan | Director | May 21, 2026 |
| Ian Sheffield | Director | Sep 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Robert D. Iii Allen | Chief Scientific Officer | Aug 18, 2026 |
| Jill Andersen | Chief Legal Officer, Secretary | Aug 18, 2026 |
| William E. Duke | Chief Financial Officer | Aug 18, 2026 |
| Marc Elia | Chief Executive Officer | Sep 1, 2026 |
| Julie Green | Chief Human Resources Officer | Aug 18, 2026 |
| Timothy Edward Lee | Chief Commercial Officer | Aug 18, 2026 |
| Michael Mina | CMO and Chief Epidemiologist | Aug 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | William E. Duke | Sale | 18,425 | $0.84 |
| Aug 18, 2026 | Robert D. Iii Allen | Sale | 17,043 | $0.84 |
| Aug 18, 2026 | Jill Andersen | Sale | 30,706 | $0.84 |
| Aug 18, 2026 | Timothy Edward Lee | Sale | 18,425 | $0.84 |
| Aug 18, 2026 | Julie Green | Sale | 18,425 | $0.84 |
| Aug 17, 2026 | William E. Duke | Sale | 22,355 | $0.72 |
| Aug 17, 2026 | Robert D. Iii Allen | Sale | 20,679 | $0.72 |
| Aug 17, 2026 | Jill Andersen | Sale | 37,256 | $0.72 |
| Aug 17, 2026 | Timothy Edward Lee | Sale | 22,355 | $0.72 |
| Aug 17, 2026 | Julie Green | Sale | 22,355 | $0.72 |
| Feb 18, 2026 | Timothy Edward Lee | Sale | 20,964 | $1.58 |
| Feb 18, 2026 | Jill Andersen | Sale | 34,939 | $1.58 |
| Feb 18, 2026 | Julie Green | Sale | 20,964 | $1.58 |
| Feb 18, 2026 | William E. Duke | Sale | 20,964 | $1.58 |
| Feb 18, 2026 | Robert D. Iii Allen | Sale | 19,392 | $1.58 |
IVVD financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $53.43M | $-52.49M | -0.30 | $-58.13M |
| Dec 31, 2024 | $25.38M | $-169.93M | -1.43 | $-170.49M |
| Dec 31, 2023 | $0 | $-198.64M | -1.81 | $-173.16M |
| Dec 31, 2022 | — | $-241.32M | -2.23 | $-219.99M |
| Dec 31, 2021 | — | $-226.79M | -5.32 | $-184.74M |
Latest balance sheet: total assets $218.88M, total liabilities $37.80M, cash $160.08M (as of Jun 30, 2026).
IVVD earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $0.69 |
| May 14, 2026 | 8-K Item 2.02 (results) | $1.16 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $1.74 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $2.51 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $1.54 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $0.80 |
| May 15, 2025 | 8-K Item 2.02 (results) | $0.70 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $0.74 |
| Feb 3, 2025 | 8-K Item 2.02 (results) | $1.06 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $0.79 |
| Oct 29, 2024 | 8-K Item 2.02 (results) | $0.91 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on IVVD
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.